share_log

HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $105 Price Target

Benzinga ·  Mar 6 20:41

HC Wainwright & Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $105 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment